Cargando…

Hepatic inflammation: an important target for biomarker development in nonalcoholic fatty liver disease

Detalles Bibliográficos
Autores principales:	Khan, Hiba, Siddiqui, Mohammad Shadab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282669/ https://www.ncbi.nlm.nih.gov/pubmed/37351134 http://dx.doi.org/10.21037/hbsn-23-196

Ejemplares similares

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease
por: Hernandez Roman, Jose, et al.
Publicado: (2020)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
por: Martínez-Beamonte, Roberto, et al.
Publicado: (2020)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?
por: Patoulias, Dimitrios
Publicado: (2021)

It’s Ready for Targeting Muscle in Nonalcoholic Fatty Liver in This Era of Aging
por: Joo, Sae Kyung, et al.
Publicado: (2019)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
por: Kim, Sang Yong
Publicado: (2013)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Treating Nonalcoholic Fatty Liver Disease From the Outside In?
por: Flynn, Charles R.
Publicado: (2019)

Imaging methods in the assessment of nonalcoholic fatty liver disease
por: Parente, Daniella Braz
Publicado: (2020)

Hepatic Innervations and Nonalcoholic Fatty Liver Disease
por: Adori, Monika, et al.
Publicado: (2023)

Early but Not Late Exercise Training in Mice Exacerbates Hepatic Inflammation in Developing Nonalcoholic Fatty Liver Disease
por: Kovynev, Artemiy, et al.
Publicado: (2023)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease: Diagnostic biomarkers
por: Hadizadeh, Fatemeh, et al.
Publicado: (2017)

Importance of Variables in Nonalcoholic Fatty Liver Disease Patients
por: Garg, Vivek Kumar, et al.
Publicado: (2018)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
por: Park, Ji-Won, et al.
Publicado: (2023)

Body fat distribution: a crucial target for intervention in nonalcoholic fatty liver disease and fibrosis
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
por: Pedersen, Julie Steen, et al.
Publicado: (2020)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
por: Chrysavgis, Lampros, et al.
Publicado: (2020)

Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease
por: Noh, Junghyun
Publicado: (2020)

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
por: Ren, Tian-Yi, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease – a growing public health problem
por: Mikolašević, Ivana, et al.
Publicado: (2021)

The role of magnetic resonance elastography in the evaluation of nonalcoholic fatty liver disease
por: Idilman, Ilkay S., et al.
Publicado: (2023)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
por: Kang, Seong Hee, et al.
Publicado: (2023)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
por: Chun, Ho Soo
Publicado: (2023)

Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease
por: Jayasekera, Dulshan, et al.
Publicado: (2023)

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
por: Gîlcă-Blanariu, Georgiana-Emmanuela, et al.
Publicado: (2023)

Hepatic and Splenic Volumetry Could Be Used as an Imaging Parameter to Evaluate Fibrosis Grades of the Diffuse Liver Disease Including Nonalcoholic Fatty Liver Disease
por: Jeong, Woo Kyoung
Publicado: (2017)

Metabolic Targets in Nonalcoholic Fatty Liver Disease
por: Esler, William P., et al.
Publicado: (2019)

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
por: Chuah, Kee-Huat, et al.
Publicado: (2023)

The transcontinental variability of nonalcoholic fatty liver disease
por: Oliveira, Claudia P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rn7cngkcu8krvr0ujahp309l3q